Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10623847 | 0.81 | MEN1 (0.31) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL5847222 | 0.76 | MEN1 (0.34) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL9698326 | 0.75 | MEN1 (0.33) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL18877228 | 0.74 | MEN1 (0.35) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL10500851 | 0.71 | MEN1 (0.33) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL12475543 | 0.71 | MEN1 (0.33) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL9638912 | 0.71 | MAPT (0.36) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL4616283 | 0.71 | MEN1 (0.33) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL18877226 | 0.69 | LMNA (0.39) | MEN1CYP2C19RECQLKMT2AMAPT | |
| SCHEMBL7528074 | 0.69 | MEN1 (0.33) | MEN1CYP2C19RECQLKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0135400-B1 | ESTRADIENE DERIVATIVES LABELLED WITH TRITIUM, THEIR PREPARATION AND INTERMEDIATES FOR THEIR PREPARATION, AND THEIR UTILIZATION IN THE STUDY AND IN THE DETERMINATION OF STEROIDS IN BIOLOGICAL FLUIDS | ROUSSEL-UCLAF (FR) | 1988-06-01 | — | — | EP | claimed |
| EP-0102531-B1 | PROCESS FOR THE PREPARATION OF COMPOUNDS OF THE MEGASTIGMAN-SERIES, AND INTERMEDIATES FOR THIS SYNTHESIS | BASF Aktiengesellschaft (DE) | 1988-03-02 | — | — | EP | claimed |
| EP-0102531-A2 | Process for the preparation of compounds of the megastigman-series, and intermediates for this synthesis | BASF Aktiengesellschaft (DE) | 1984-03-14 | — | — | EP | claimed |
| EP-1365768-B1 | USE OF ER-BETA SELECTIVE ANTAGONISTS AS CONTRACEPTIVES | BAYER SCHERING PHARMA AG (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-20070191334-A1 | Tricyclic imidazopyridines | ALTANA PHARMA AG (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1735318-A2 | 7H-8,9-DIHYDRO-PYRANO(2,3-C)IMIDAZO(1,2A)PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-12-27 | — | — | EP | disclosed |
| WO-2005090358-A2 | 7H-8,9-DIHYDRO-PYRANO (2,3-C) IMIDAZO (1,2A) PYRIDINE DERIVATIVES AND THEIR USE AS GASTRIC ACID SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-29 | — | — | WO | disclosed |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-01-27 | — | — | US | disclosed |
| US-6794409-B2 | HOMOSTEROIDS SUCH AS 17-CHLORO-17A-ALPHA-ETHINYL-17A, 18A-DIHOMO-ESTRA-1,3,5(10),16-TETRAENE-3,17A BETA-DIOL; WITHOUT USE OF PROGESTIN; CONTRACEPTION; FOR TREATMENT OF PROLIFERATIVE DISEASES OF THE OVARY | SCHERING AG (DE) | 2004-09-21 | — | — | US | disclosed |
| EP-1365768-A2 | USE OF ERSS-SELECTIVE LIGANDS FOR REGULATING FERTILITY AND COMPOUNDS USEFUL THEREFORE | Schering Aktiengesellschaft (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-05-01 | — | — | US | disclosed |
| EP-0019247-B1 | 16-ALPHA-ALKYL STEROIDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-11-25 | — | — | EP | disclosed |
| EP-0019247-A1 | 16-Alpha-alkyl steroids, process for their preparation and pharmaceutical compositions containing them | SCHERING AKTIENGESELLSCHAFT (DE) | 1980-11-26 | — | — | EP | disclosed |
| EP-0015436-A1 | Process for the stereospecific preparation of compounds of the vitamin K1- and K2-series, as well as new starting materials for the process | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-09-17 | — | — | EP | disclosed |
| US-4016269-A | 17α-HYDROXY-1,3,5(10),15-ESTRATETRAENES AND PROCESS FOR THEIR PRODUCTION | SCHERING AKTIENGESELLSCHAFT (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3994937-A | ANABOLIC, ANDROGENIC, GESTAGENIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-11-30 | — | — | US | disclosed |
| US-3966713-A | 11β-FLUOROANDROSTENES | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-06-29 | — | — | US | disclosed |
| US-3960841-A | ESTROGENIC DEFICIENCY TREATMENT | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-06-01 | — | — | US | disclosed |
| US-3951958-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
| US-3951959-A | VAGINOTROPIC | SCHERING AKTIENGESELLSCHAFT (DT) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083377-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESRRB, ESR2 | MEN1 3807/4885CYP2C19 3872/4885RECQL 4258/4885 |
| US-20050020695-A1 | Use of ERbeta-selective ligands for regulating fertility and compounds useful therefor | ESRRA, ESR2, ESRRB | MEN1 3866/4885CYP2C19 3872/4885RECQL 4309/4885 |
| US-20070191334-A1 | Tricyclic imidazopyridines | GIPR, SLC10A2, MLNR | MEN1 1765/4885CYP2C19 38/4885RECQL 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.